SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced positive results from a recently completed clinical trial with immediate-release ZEGERID® (omeprazole/sodium bicarbonate) Capsules 40 mg/1100 mg and two leading proton pump inhibitors (PPIs), Protonix® (pantoprazole sodium) delayed-release tablets 40 mg and Prevacid® (lansoprazole) delayed-release capsules 30 mg. The study evaluated the effect of morning PPI dosing on 24-hour gastric acid control in patients with symptoms of gastroesophageal reflux disease (GERD).
